Latest news for Ensurge Micropower (OTC:ENMPY) Stock

Ensurge Micropower ASA is Energizing Innovation with ultrathin, flexible, and safe energy storage solutions for wearable devices, connected sensors, and beyond. Thinfilm's solid-state lithium battery (SSLB) technology is positioned to enable the production of powerful, lightweight, and cost-effective rechargeable batteries for diverse applications. The company's flexible electronics manufacturing facility, located in the heart of Silicon Valley, combines patented process technology and materials with the scale of roll-to-roll production methods to bring the advantages of SSLB technology to established and expanding markets.

ENSURGE MICROPOWER S/ADR by Ensurge Micropower ASA

Ensurge Micropower ASA

<p>Hydrogen buyers now have the freedom to purchase liquid green hydrogen from Plug's production plants on-demand and without the limitations of long-term take-or-pay agreements.&nbsp;</p>


News

PLUG

Plug Power Introduces Spot Pricing Program For Liquid Green Hydrogen; Enters Into Spot Pricing Agreements With Several Industry Players

Earnings

Earnings Beats

Aurora Cannabis Q3 Total Net Revenue C$88.2M, Up 37% YoY

Guidance

PFGC

Performance Food Sees Q3 Sales Of $15.2B - $15.6B Vs. $15.26B Est; Adj EBITDA Of $390M - $410M.

<p><strong>Guidance and Outlook</strong></p>
<p>Spire continues to expect fiscal 2025 adjusted earnings to be in the range of $4.40–$4.60 per share. We remain confident in our ability to grow long-term adjusted earnings per share 5–7% driven by an expected long-term 7–8% annualized rate base growth at Spire Missouri, reflecting our robust capital investment plan, and 6% equity growth at Spire Alabama and Spire Gulf.</p>
<p>Our 10-year $7.4 billion capital investment target through fiscal 2034 is driven by increasing investment in infrastructure upgrades and new business in the Gas Utility segment. Expected total capital expenditures for fiscal 2025 remains $790 million.</p>


Commodities

Markets

General

Spire Continues To Expect Fiscal 2025 Adjusted Earnings Of $4.40–$4.60 Per Share Compared To Consensus Of $4.50

<p>New York Times (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.74 by 8.11 percent. This is a 14.29 percent increase over earnings of $0.70 per share from the same period last year.  The company reported quarterly sales of $726.60 million which missed the analyst consensus estimate of $726.65 million by 0.01 percent.  This is a 7.45 percent increase over sales of $676.22 million the same period last year.</p>


Earnings Misses

New York Times Q4 2024 Adj EPS $0.80 Beats $0.74 Estimate, Sales $726.60M Miss $726.65M Estimate

<p>Reynolds Consumer Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REYN#NASDAQ">REYN</a>) reported quarterly earnings of $0.58 per share which met the analyst consensus estimate. This is a 10.77 percent decrease over earnings of $0.65 per share from the same period last year.  The company reported quarterly sales of $1.02 billion which beat the analyst consensus estimate of $971.86 million by 5.06 percent.  This is a 1.39 percent increase over sales of $1.01 billion the same period last year.</p>


REYN

Reynolds Consumer Prods Q4 2024 Adj EPS $0.58, Inline, Sales $1.02B Beat $971.86M Estimate

<p>CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) reported quarterly earnings of $2.48 per share which beat the analyst consensus estimate of $2.32 by 6.9 percent. This is a 3.5 percent decrease over earnings of $2.57 per share from the same period last year.  The company reported quarterly sales of $5.186 billion which beat the analyst consensus estimate of $4.954 billion by 4.69 percent.  This is a 3.33 percent increase over sales of $5.019 billion the same period last year.</p>


CDW Q4 2024 Adj. EPS $2.48 Beats $2.32 Estimate, Sales $5.186B Beat $4.954B Estimate

<p>Catapult Health's trailing twelve-month revenue was approximately $30 million as of the third quarter of 2024. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions.</p>
<p>Following the closing of the transaction, Catapult Health will operate within the Integrated Care segment of Teladoc Health.</p>
<p><br />&nbsp;</p>


TDOC

Teladoc Health To Acquire Catapult Health In An All-cash Transaction For $65M, With Up To $5M In Additional Contingent Earnout Consideration

AZTA

Azenta Q1 2025 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $147.510M Beat $146.190M Estimate

Fiserv Sees FY25 Adj. EPS $10.10-$10.30 vs $10.20 Est., Organic Revenue Growth 10-12%

Emerson Sees Q2 2025 Net Sales Growth -0.5%-0.5%; Sees FY25 Net Sales Growth 1.5%-3.5%

<p>Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) reported quarterly earnings of $1.23 per share which beat the analyst consensus estimate of $1.18 by 4.24 percent. This is a 16.33 percent decrease over earnings of $1.47 per share from the same period last year.  The company reported quarterly sales of $1.386 billion which beat the analyst consensus estimate of $1.379 billion by 0.48 percent.  This is a 7.36 percent decrease over sales of $1.496 billion the same period last year.</p>


ODFL

Old Dominion Freight Line Q4 2024 GAAP EPS $1.23 Beats $1.18 Estimate, Sales $1.386B Beat $1.379B Estimate

<p>Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) reported quarterly earnings of $1.34 per share which missed the analyst consensus estimate of $1.42 by 5.63 percent. This is a 8.84 percent decrease over earnings of $1.47 per share from the same period last year.  The company reported quarterly sales of $669.10 million which missed the analyst consensus estimate of $756.50 million by 11.55 percent.  This is a 11.56 percent decrease over sales of $756.60 million the same period last year.</p>


Spire Q1 2025 Adj EPS $1.34 Misses $1.42 Estimate, Sales $669.10M Miss $756.50M Estimate

<p>Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) reported quarterly adjusted earnings of $0.98 per share which missed the analyst consensus estimate of $1.05 by 6.67 percent. This is a 8.89 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $15.64 billion which beat the analyst consensus estimate of $15.50 billion by 0.88 percent. This is a 9.39 percent increase over sales of $14.30 billion the same period last year.</p>


Performance Food Gr Q2 Adj $0.98 Misses $1.05 Estimate, Sales $15.64B Beat $15.50B Estimate

Fiserv Q4 2024 Adj. EPS $2.51 Beats $2.48 Estimate, Sales $5.25B Beat $4.961B Estimate

CRTO

Criteo Q4 2024 Adj. EPS $1.75 Beats $1.36 Estimate, Sales $553.035M Beat $328.116M Estimate

<p>JMP Securities  analyst David Scharf   maintains Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Market Outperform and raises the price target from $125 to $135.</p>


Price Target

Analyst Ratings

ENVA

JMP Securities Maintains Market Outperform on Enova International, Raises Price Target to $135

<p>Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.45 by 33.33 percent. This is a 20 percent increase over earnings of $0.50 per share from the same period last year.  The company reported quarterly sales of $465.20 million which beat the analyst consensus estimate of $455.08 million by 2.22 percent.  This is a 16.39 percent increase over sales of $399.70 million the same period last year.</p>


Dayforce Q4 2024 Adj EPS $0.60 Beats $0.45 Estimate, Sales $465.20M Beat $455.08M Estimate

<p>In the latest quarter, 8 analysts provided ratings for Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Snap and provided 12-month price targets. The average target is $14.39, accompanied by a high estimate of $16.00 and a low estimate of $11.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.51%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738756856_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Snap among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.11</td>
<td>$12.11</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Snap. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Snap compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Snap's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Snap's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNAP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Snap analyst ratings.</strong></a></p>
<h2>Delving into Snap's Background</h2>
<p>Snap is a technology company best known for its marquis social media application Snapchat, a visual messaging application that has amassed hundreds of millions of users. The app was initially only used to communicate with family and friends through photographs and short videos (known as "Snaps"). Users can now enjoy augmented reality, or AR, lenses, content from famous creators and celebrities, updates about local events, and more. Although the app offers a paid subscription option with premium features, advertising sales produce most of the app's revenue. The firm also sells wearable devices called AR Spectacles, which can capture photos and videos overlayed with AR lenses, but these make up a small portion of Snap's overall sales.</p>
<h3>A Deep Dive into Snap's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Snap's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>15.48%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Snap's net margin is impressive, surpassing industry averages. With a net margin of <strong>-11.16%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Snap's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-7.17%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Snap's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.04%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.92</strong>, Snap faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SNAP

What Analysts Are Saying About Snap Stock

<p>During the last three months, 8 analysts shared their evaluations of TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated TransMedics Gr and provided 12-month price targets. The average target is $106.62, accompanied by a high estimate of $125.00 and a low estimate of $75.00. Highlighting a 20.58% decrease, the current average has fallen from the previous average price target of $134.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738756849_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive TransMedics Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$109.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to TransMedics Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TransMedics Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for TransMedics Gr's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TransMedics Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TMDX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on TransMedics Gr analyst ratings.</strong></a></p>
<h2>About TransMedics Gr</h2>
<p>TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.</p>
<h3>TransMedics Gr's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining TransMedics Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>63.72%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> TransMedics Gr's net margin is impressive, surpassing industry averages. With a net margin of <strong>3.88%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> TransMedics Gr's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.11%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.55%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> TransMedics Gr's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.47</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Ensurge Micropower

News

Latest news for Ensurge Micropower (OTC:ENMPY) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga